Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Controlling COVID-19 via test-trace-quarantine

Cliff C. Kerr, Dina Mistry, Robyn M. Stuart, Katherine Rosenfeld, Gregory R. Hart, Rafael C. Núñez, Jamie A. Cohen, Prashanth Selvaraj, Romesh G. Abeysuriya, Michał Jastrzębski, Lauren George, Brittany Hagedorn, View ORCID ProfileJasmina Panovska-Griffiths, Meaghan Fagalde, Jeffrey Duchin, Michael Famulare, Daniel J. Klein
doi: https://doi.org/10.1101/2020.07.15.20154765
Cliff C. Kerr
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ckerr@idmod.org
Dina Mistry
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robyn M. Stuart
2Department of Mathematical Sciences, University of Copenhagen, Copenhagen, Denmark
3Burnet Institute, Melbourne, VIC, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Rosenfeld
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory R. Hart
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael C. Núñez
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie A. Cohen
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prashanth Selvaraj
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romesh G. Abeysuriya
3Burnet Institute, Melbourne, VIC, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michał Jastrzębski
4GitHub, Inc., San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren George
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brittany Hagedorn
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasmina Panovska-Griffiths
5Department of Applied Health Research, University College London, London, UK
6Wolfson Centre for Mathematical Biology and The Queen’s College, Oxford University, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jasmina Panovska-Griffiths
Meaghan Fagalde
7Seattle-King County Health Authority, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Duchin
7Seattle-King County Health Authority, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Famulare
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J. Klein
1Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Initial COVID-19 containment in the United States focused on limiting mobility, including school and workplace closures. However, these interventions have had enormous societal and economic costs. Here we demonstrate the feasibility of an alternative control strategy, test-trace-quarantine: routine testing of primarily symptomatic individuals, tracing and testing their known contacts, and placing their contacts in quarantine. We performed this analysis using Covasim, an open-source agent-based model, which was calibrated to detailed demographic, mobility, and epidemiological data for the Seattle region from January through June 2020. With current levels of mask use and schools remaining closed, we found that high but achievable levels of testing and tracing are sufficient to maintain epidemic control even under a return to full workplace and community mobility and with low vaccine coverage. The easing of mobility restrictions in June 2020 and subsequent scale-up of testing and tracing programs through September provided real-world validation of our predictions. Although we show that test-trace-quarantine can control the epidemic in both theory and practice, its success is contingent on high testing and tracing rates, high quarantine compliance, relatively short testing and tracing delays, and moderate to high mask use. Thus, in order for test-trace-quarantine to control transmission with a return to high mobility, strong performance in all aspects of the program is required.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding was provided by the Bill and Melinda Gates Foundation. Institutional support, including high-performance computing resources and library access, was provided by the Burnet Institute and the University of Sydney School of Physics.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The Covasim model code is fully open source and available via GitHub: https://github.com/institutefordiseasemodeling/covasim Epidemiological data used in this study are available from the King County Data Dashboard: https://www.kingcounty.gov/depts/health/covid-19/data.aspx SafeGraph mobility data are available from: https://www.safegraph.com/data-examples/covid19-commerce-patterns

https://github.com/institutefordiseasemodeling/covasim

https://www.kingcounty.gov/depts/health/covid-19/data.aspx

https://www.safegraph.com/data-examples/covid19-commerce-patterns

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 23, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Controlling COVID-19 via test-trace-quarantine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Controlling COVID-19 via test-trace-quarantine
Cliff C. Kerr, Dina Mistry, Robyn M. Stuart, Katherine Rosenfeld, Gregory R. Hart, Rafael C. Núñez, Jamie A. Cohen, Prashanth Selvaraj, Romesh G. Abeysuriya, Michał Jastrzębski, Lauren George, Brittany Hagedorn, Jasmina Panovska-Griffiths, Meaghan Fagalde, Jeffrey Duchin, Michael Famulare, Daniel J. Klein
medRxiv 2020.07.15.20154765; doi: https://doi.org/10.1101/2020.07.15.20154765
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Controlling COVID-19 via test-trace-quarantine
Cliff C. Kerr, Dina Mistry, Robyn M. Stuart, Katherine Rosenfeld, Gregory R. Hart, Rafael C. Núñez, Jamie A. Cohen, Prashanth Selvaraj, Romesh G. Abeysuriya, Michał Jastrzębski, Lauren George, Brittany Hagedorn, Jasmina Panovska-Griffiths, Meaghan Fagalde, Jeffrey Duchin, Michael Famulare, Daniel J. Klein
medRxiv 2020.07.15.20154765; doi: https://doi.org/10.1101/2020.07.15.20154765

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (157)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (852)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8528)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1731)
  • Geriatric Medicine (166)
  • Health Economics (370)
  • Health Informatics (1232)
  • Health Policy (615)
  • Health Systems and Quality Improvement (465)
  • Hematology (196)
  • HIV/AIDS (367)
  • Infectious Diseases (except HIV/AIDS) (10258)
  • Intensive Care and Critical Care Medicine (550)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (209)
  • Neurology (1662)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (321)
  • Occupational and Environmental Health (450)
  • Oncology (918)
  • Ophthalmology (261)
  • Orthopedics (99)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (532)
  • Pharmacology and Therapeutics (245)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1751)
  • Public and Global Health (3814)
  • Radiology and Imaging (620)
  • Rehabilitation Medicine and Physical Therapy (316)
  • Respiratory Medicine (518)
  • Rheumatology (204)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (188)
  • Toxicology (36)
  • Transplantation (99)
  • Urology (74)